Bicara Therapeutics Inc. Common Stock (BCAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has a cash flow conversion efficiency ratio of -0.073x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-37.51 Million) by net assets ($513.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bicara Therapeutics Inc. Common Stock (BCAX) defensive interval to measure how many days the company can operate on defensive assets alone.
Bicara Therapeutics Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bicara Therapeutics Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xiamen Guang Pu Electronics Co Ltd
SHE:300632
|
0.003x |
|
Gravita India Limited
NSE:GRAVITA
|
-0.021x |
|
Laobaixing Pharmacy
SHG:603883
|
0.074x |
|
Borr Drilling Ltd
NYSE:BORR
|
0.028x |
|
Kelt Exploration Ltd.
TO:KEL
|
0.048x |
|
Kuangda Technology Group Co Ltd
SHE:002516
|
0.058x |
|
OC OERL.CORP ADR 2 SF 1
F:OBH0
|
N/A |
|
Shanghai SMI Holding Co Ltd
SHG:600649
|
0.039x |
Annual Cash Flow Conversion Efficiency for Bicara Therapeutics Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Bicara Therapeutics Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Bicara Therapeutics Inc. Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $401.45 Million | $-106.83 Million | -0.266x | -75.11% |
| 2024-12-31 | $491.88 Million | $-74.75 Million | -0.152x | +27.22% |
| 2023-12-31 | $218.51 Million | $-45.63 Million | -0.209x | -111.25% |
| 2022-12-31 | $-17.28 Million | $-32.08 Million | 1.856x | -- |
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was … Read more